CAMBRIDGE, Mass., Nov. 15 /PRNewswire-FirstCall/ -- Xanthus Life Sciences,
Inc., a privately-held oncology drug development company, today announced that
J. Kris Piper has joined the Xanthus management team as Vice President of
Regulatory Affairs and Quality Assurance.
"Kris brings to Xanthus an extensive set of global regulatory
accomplishments in both therapeutic and imaging product development which, I
know from our prior working experience, will complement and strengthen the
considerable expertise of our senior management team. In prior positions,
Kris has been responsible for the filing and subsequent approval of over 20
NDAs, three of which were priority review products. Additionally, Kris has
also been responsible for implementing the various policies and procedures
necessary to assure product quality and regulatory compliance," stated Richard
T. Dean, Ph.D., President and CEO of Xanthus. "We are pleased to welcome Kris
to Xanthus and look forward to the important contributions he will make as we
advance our pipeline of oncology therapeutics and expand into new indications
of unmet medical need."
J. Kris Piper joins Xanthus from Bracco S.p.A. where he was Vice President
Global Preclinical and Clinical Regulatory Affairs. Prior to Bracco, Mr.
Piper was Vice President Regulatory Affairs at Schering AG where he was
responsible for all regulatory affairs activities for products at Schering's
Berlex and Diatide subsidiaries. Mr. Piper also held Director and Manager
level positions in Regulatory Affairs and Quality Assurance for Mallinckrodt
Medical, Inc., American Hospital Supply Corporation, Searle Pharmaceuticals,
Inc. and Bayer Healthcare's Cutter Laboratories, Inc. Mr. Piper is a graduate
of University of California, Davis where he also received his Master of
Science Degree in Physiology.
About Xanthus Life Sciences, Inc.
Xanthus Life Sciences, Inc. is developing a portfolio of novel, clinical-
stage, small-molecule oncology candidates through a management team whose
accomplished track record encompasses all aspects of drug development, from
discovery through regulatory approval and commercialization. The Company is
applying its expertise both to advance its current pipeline and expand it into
indications of unmet medical need beyond oncology.
Xanthus is headquartered in Cambridge, Massachusetts with an additional
facility in Montreal, Quebec. More information is available at
http://www.xanthus.com.
Contacts:
Kari Watson, MacDougall Biomedical Communications, Inc.
kwatson@macbiocom.com or (508) 647-0209
John A. McCarthy, Jr., Senior Vice President and Chief Financial Officer,
Xanthus Life Sciences, Inc. - (617) 225-0522 x125
SOURCE Xanthus Life Sciences, Inc.
 back to top
Related links:
http://www.xanthus.com
CONTACT:
Kari Watson of MacDougall Biomedical
Communications, Inc., kwatson@macbiocom.com, +1-508-647-0209; or
John A. McCarthy, Jr., Senior Vice President and Chief Financial
Officer of Xanthus Life Sciences, Inc., +1-617- 225-0522 ext 125
|
